Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT02955615 is registered in ClinicalTrials.gov with Iltoo Pharma as lead sponsor.

NCT NCT02955615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
Lead sponsor
Iltoo Pharma
Phase
Phase 2
Overall status
Completed
Start date
January 18, 2017
Completion date
February 11, 2019
Enrollment
100 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus